We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: May 5, 2009
Last Update Posted: March 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Heartcenter Leipzig GmbH
Information provided by (Responsible Party):
Sven Möbius-Winkler, University of Leipzig

Pulmonary Hypertension (PH) is a disease that is characterized by vasoconstriction of small vessels of the lung. Many cases do have proliferation of endothelial cells within these vessels. A possible influence of polymorphisms of genes relevant for inflammatory and endothelial processes is suspected.

Especially patients with chronic heart failure can develope PH. The reasons therefore are lacking.

The researchers investigate different polymorphism and the influence of these on pulmonary artery pressure (measured invasively) in patients with congestive heart failure (CHF) and patients with primary pulmonary hypertension.

Congestive Heart Failure Pulmonary Hypertension

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Impact of Different Genetic Polymorphism on the Pulmonary Pressure in Patients With Pulmonary Hypertension of Different Cause With Special Focus on Patients With Chronic Heart Failure

Resource links provided by NLM:

Further study details as provided by Sven Möbius-Winkler, University of Leipzig:

Primary Outcome Measures:
  • Correlation of the Expression of Glu 298ASP Polymorphism with pulmonary pressure [ Time Frame: Dec. 2010 ]

Secondary Outcome Measures:
  • Rate of G308A TNF alpha polymorphism within the different groups [ Time Frame: Dec. 2010 ]

Biospecimen Retention:   Samples With DNA
EDTA Blood, Serum

Estimated Enrollment: 600
Actual Study Start Date: December 2007
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
CHF with elevated PAP
CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
CHF patient without elevated PAP
CHF patients (LVEF > 35%) with normal mean pulmonary pressure
Normal EF with elevated PAP
Patients with normal LVEF < 60% with elevated mean pulmonary pressure

Detailed Description:

The study consists of 3 arms-patients with CHF and PH, patients with CHF without PH and patients without CHF and PH.

The PH measurement is due to routine catheterization, thereafter we measure different vasoactive polymorphism.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
CHF elevated pulmonary hypertension

Inclusion Criteria:

  • CHF with or without pulmonary hypertension or
  • patients with normal LVEF and pulmonary hypertension
  • right heart catheterization due to routine
  • informed consent

Exclusion Criteria:

  • no right heart catheterization
  • no informed consent
  • elevated pulmonary pressure due to valve diseases or congenital heart disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00893178

Heart Center Leipzig- University Leipzig
Leipzig, Germany, 04289
Sponsors and Collaborators
University of Leipzig
Heartcenter Leipzig GmbH
Principal Investigator: Sven Möbius-Winkler, M.D University Leipzig-Heart Center
  More Information

Responsible Party: Sven Möbius-Winkler, PI, University of Leipzig
ClinicalTrials.gov Identifier: NCT00893178     History of Changes
Other Study ID Numbers: SMW 03
First Submitted: May 1, 2009
First Posted: May 5, 2009
Last Update Posted: March 15, 2017
Last Verified: March 2017

Keywords provided by Sven Möbius-Winkler, University of Leipzig:
eNOS Polymorphism
TNF alpha polymorphism
pulmonary pressure
polymorphism of vasoactive substances

Additional relevant MeSH terms:
Heart Failure
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Lung Diseases
Respiratory Tract Diseases